Skip to main content
Evidence Snapshot

Acetylcholinesterase

CHEMBL4078 SINGLE PROTEIN Electrophorus electricus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:25Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4078
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Acetylcholinesterase as ChEMBL target CHEMBL4078, mapped to UniProt O42275. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Acetylcholinesterase
SINGLE PROTEIN · Electrophorus electricus
As of 2026-09-13
ChEMBL target ID
CHEMBL4078
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O42275
Acetylcholinesterase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Acetylcholinesterase matters

As of 2026-09-13

Acetylcholinesterase is reviewed as Acetylcholinesterase (UniProt O42275); the current evidence base includes 33 approved drugs, 9325 compounds, and 1451 assays, with lead potency reaching pChEMBL 10.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 33 approved drugs, 9325 compounds, and 1451 assays for this target. The dominant activity type is IC50. CHEMBL32823 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL32823 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
33 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Acetylcholinesterase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O42275, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

9325
Total Compounds
1451
Total Assays
33
Approved Drugs
IC50: 7733.0, KI: 736.0, EC50: 2.0, KD: 22.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
10.5 IC50
No preferred name
CHEMBL4749763
10.4 Ki
No preferred name
CHEMBL238756
10.2 Ki
No preferred name
CHEMBL1161905
10.2 IC50
No preferred name
CHEMBL140476
10.1 IC50

Approved Drugs

Structure Compound First Approval
NEOSTIGMINE
CHEMBL278020
2013
HYDROQUINONE
CHEMBL537
2002
GALANTAMINE
CHEMBL659
2001
2001
DONEPEZIL
CHEMBL502
1996
1996
TACRINE
CHEMBL95
1993
1993
ISOFLUROPHATE
CHEMBL1025
1957
BERBERINE
CHEMBL295124
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:25Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4078